1. |
Ferlay J, Shin H, Bray F, et al. GLOBOCAN 2008, cancer incidence and mortality worldwide: IARC CancerBase No. 10. Lyon, France. 2010-08-01. http://globocan.iarc.fr.
|
2. |
Carethers JM, Jung BH. Genetics and genetic biomarkers in sporadic colorectal cancer. Gastroenterology, 2015, 149(5): 1177-1190.
|
3. |
Ahmad M, Attoub S, Singh MN, et al. Gamma-synuclein and the progression of cancer. FASEB J, 2007, 21(13): 3419-3430.
|
4. |
De Mattia E, Cecchin E, Toffoli G. Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: toward targeted personalized therapy. Drug Resist Updat, 2015, 20(4): 39-70.
|
5. |
Birkman EM, Avoranta T, Ålgars A, et al. EGFR gene copy number decreases during anti-EGFR antibody therapy in colorectal cancer. Hum Pathol, 2018, [Epub ahead of print].
|
6. |
王珊珊, 梅金红. HER2 与肿瘤浸润转移. 生命的化学, 2008, 28(5): 566-568.
|
7. |
Pandya K, Wyatt D, Gallagher B, et al. PKCα attenuates jagged-1-mediated notch signaling in ErbB-2-positive breast cancer to reverse trastuzumab resistance. Clin Cancer Res, 2016, 22(1): 175-186.
|
8. |
Lin Z, Lu Y, Meng Q, et al. miR372 promotes progression of liver cancer cells by upregulating erbB-2 through enhancement of YB-1. Mol Ther Nucleic Acids, 2018, 11: 494-507.
|
9. |
Testa U, Pelosi E, Castelli G. Colorectal cancer: genetic abnormalities, tumor progression, tumor heterogeneity, clonal evolution and tumor-initiating cells. Med Sci (Basel), 2018, 6(2): 31-41.
|
10. |
李春莲, 周旭婕, 娄培培, 等. RNA 结合蛋白 38 通过增加人表皮生长因子受体 2 的表达诱导乳腺癌 BT474 细胞对曲妥珠单抗的敏感性. 中华肿瘤杂志, 2016, 38(3): 172-178.
|
11. |
许惠玉, 陈志伟, 郭洪英. 岩大戟内酯 B 诱导乳腺癌 MCF7 细胞凋亡实验研究. 中国医学创新, 2012, 9(13): 1-3.
|
12. |
Pan G, Li D, Li X, et al. SPECT/CT imaging of HER2 expression in colon cancer-bearing nude mice using. Biochem Biophys Res Commun, 2018, 504(4): 765-770.
|
13. |
Takegawa N, Yonesaka K. HER2 as an emerging oncotarget for colorectal cancer treatment after failure of anti-epidermal growth factor receptor therapy. Clin Colorectal Cancer, 2017, 16(4): 247-251.
|
14. |
Ménard S, Casalini P, Campiglio M, et al. HER2 overexpression in various tumor types, focussing on its relationship to the development of invasive breast cancer. Ann Oncol, 2001, 12(Suppl 1): S15-S19.
|
15. |
Lee JH, Kim HM, Koo JS. Differential expression of cancer-associated fibroblast-related proteins in ductal carcinoma in situ according to molecular subtype and stromal histology. Pathobiology, 2018, 17(6): 1-11.
|
16. |
梁霞, 张勇晶, 刘冰, 等. HER-2 基因 Ile655Val 多态性与结直肠癌易感性分析. 中华医学遗传学杂志, 2009, 26(3): 302-305.
|
17. |
Buhmeida A, Assidi M, Al-Maghrabi J, et al. Membranous or cytoplasmic HER2 expression in colorectal carcinoma: evaluation of prognostic value using both IHC – BDISH. Cancer Invest, 2018, 36(2): 129-140.
|
18. |
李东升, 王巍, 李晴, 等. 结直肠癌组织中 Her-2 和 Claudin-1 的表达及意义. 广东医学, 2012, 33(2): 237-239.
|
19. |
Zhu H, Zhang G, Wang Y, et al. Inhibition of ErbB2 by Herceptin reduces survivin expression via the ErbB2-beta-catenin/TCF4-survivin pathway in ErbB2-overexpressed breast cancer cells. Cancer Sci, 2010, 101(5): 1156-1162.
|
20. |
Rebischung C, Barnoud R, Stéfani L, et al. The effectiveness of trastuzumab (Herceptin) combined with chemotherapy for gastric carcinoma with overexpression of the c-erbB-2 protein. Gastric Cancer, 2005, 8(4): 249-252.
|
21. |
Liu D, Li X, Chen C, et al. Target-specific delivery of oxaliplatin to HER2-positive gastric cancer cells. Oncol Lett, 2018, 15(5): 8079-8087.
|
22. |
Huang R, Sun Y, Zhang XY, et al. Biological evaluation of a novel Herceptin-platinum (Ⅱ) conjugate for efficient and cancer cell specific delivery. Biomed Pharmacother, 2015, 73: 116-122.
|
23. |
Carter WB, Niu G, Ward MD, et al. Mechanisms of HER2-induced endothelial cell retraction. Ann Surg Oncol, 2007, 14(10): 2971-2978.
|
24. |
Hudziak RM, Lewis GD, Shalaby MR, et al. Amplified expression of the HER2/ERBB2 oncogene induces resistance to tumor necrosis factor alpha in NIH 3T3 cells. Proc Natl Acad Sci U S A, 1988, 85(14): 5102-5106.
|
25. |
张丽华, 李静. 曲妥珠单抗联合紫杉醇诱导过表达 HER-2 的乳腺癌裸鼠皮下移植瘤乳腺癌细胞凋亡的作用机制和效果研究. 临床和实验医学杂志, 2016, 15(14): 1373-1377.
|